Article
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2005
Mantha Angela J, Hanson Jennifer E L, Goss Glenwood, Lagarde Alain E, Lorimer Ian A, Dimitroulakos Jim
Abstract excerpt
PURPOSE: The epidermal growth factor receptor (EGFR) is a key regulator of growth, differentiation, and survival of epithelial cancers. In a small subset of tumors, the presence of activating mutations within the ATP binding site confers increased susceptibility to gefitinib, a potent tyrosine kinase inhibitor of EGFR. Agents that can inhibit EGFR function through different mechanisms may enhance gefitinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
